Lupin Limited — Investor Meet, 14-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Lupin reported a strong Q4 FY26, with revenue up 32% YoY to ₹7,475 Cr and EBITDA soaring 68% YoY to ₹2,171 Cr, yielding a 29.4% margin. Full-year FY26 revenue reached ₹27,958 Cr (+23% YoY) and EBITDA hit ₹8,160 Cr (+55% YoY), with margins at 29.7%. The US business grew 40% to USD 1.3 billion, while India prescriptions grew 10.6%.

Management projects high-single digit revenue growth and approximately 25% EBITDA margin for FY27, accounting for anticipated competition in key US products like Tolvaptan and Mirabegron. Future growth is expected from a robust US complex product pipeline, biosimilars (Pegfilgrastim, Ranibizumab), and new India launches like Semanext®. The company maintains a confident outlook, underscoring its diversified business and strong pipeline for continued growth.